• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长效抗精神病药物:标准、中等剂量及低剂量方案的比较综述

Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens.

作者信息

Kane J M, Woerner M, Sarantakos S

出版信息

J Clin Psychiatry. 1986 May;47 Suppl:30-3.

PMID:2871014
Abstract

New research in maintenance drug therapy has been influenced by a need to clarify risk-benefit ratios and determine minimum effective dosages. This research employing controlled study designs and new methods of data analysis has increased our ability to apply findings to specific patients, families, and treatment settings. Results from studies using depot neuroleptics indicate that this methodology may clarify the correlation between dose and blood levels and thus lead to the establishment of generalizable dosage guidelines. Lack of knowledge of maintenance requirements with long-acting injectable drugs may have led to the use of higher doses than necessary and an increased incidence of side effects. Recent studies suggest that with careful clinical observation, substantial reduction of maintenance doses can, for many patients, lead to improvement in some areas of subjective and objective well-being and to a diminution of adverse effects.

摘要

维持性药物治疗的新研究受到明确风险效益比和确定最低有效剂量需求的影响。这项采用对照研究设计和新数据分析方法的研究,提高了我们将研究结果应用于特定患者、家庭和治疗环境的能力。使用长效抗精神病药物的研究结果表明,这种方法可能会阐明剂量与血药浓度之间的相关性,从而有助于制定通用的剂量指南。对长效注射药物维持需求缺乏了解,可能导致使用了不必要的高剂量药物,并增加了副作用的发生率。最近的研究表明,通过仔细的临床观察,对于许多患者来说,大幅降低维持剂量可在主观和客观幸福感的某些方面带来改善,并减少不良反应。

相似文献

1
Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens.长效抗精神病药物:标准、中等剂量及低剂量方案的比较综述
J Clin Psychiatry. 1986 May;47 Suppl:30-3.
2
The use of depot neuroleptics: clinical experience in the United States.长效抗精神病药物的使用:美国的临床经验
J Clin Psychiatry. 1984 May;45(5 Pt 2):5-12.
3
The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.长效抗精神病药物的风险/效益比:斯堪的纳维亚视角
J Clin Psychiatry. 1984 May;45(5 Pt 2):22-7.
4
Antipsychotic medication: clinical guidelines for maintenance therapy.抗精神病药物:维持治疗临床指南
J Clin Psychiatry. 1985 May;46(5 Pt 2):6-15.
5
Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.长效长效抗精神病药物注射剂在精神分裂症维持治疗中的应用观察
J Clin Psychiatry. 1984 May;45(5 Pt 2):13-21.
6
[Depot antipsychotics in the year 2011].2011年的长效抗精神病药物
Tijdschr Psychiatr. 2011;53(2):95-105.
7
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.专家共识指南系列。优化精神障碍的药物治疗。引言:方法、评论与总结。
J Clin Psychiatry. 2003;64 Suppl 12:5-19.
8
Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.精神分裂症随机非典型抗精神病药物试验中的对照组偏倚。
Arch Gen Psychiatry. 2005 Sep;62(9):961-70. doi: 10.1001/archpsyc.62.9.961.
9
Clinical review of a long-acting, injectable formulation of risperidone.利培酮长效注射制剂的临床综述
Clin Ther. 2004 Dec;26(12):1994-2002. doi: 10.1016/j.clinthera.2004.12.009.
10
Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate.
J Clin Psychopharmacol. 1986 Feb;6(1 Suppl):20S-23S.

引用本文的文献

1
Fluphenazine (oral) versus placebo for schizophrenia.口服氟奋乃静与安慰剂治疗精神分裂症的比较。
Cochrane Database Syst Rev. 2018 Jun 12;6(6):CD006352. doi: 10.1002/14651858.CD006352.pub3.
2
Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.口服氟奋乃静与非典型抗精神病药物治疗精神分裂症的比较
Cochrane Database Syst Rev. 2016 Jul 2;7(7):CD010832. doi: 10.1002/14651858.CD010832.pub2.
3
Fluphenazine decanoate (depot) and enanthate for schizophrenia.癸酸氟奋乃静(长效制剂)和庚酸氟奋乃静用于治疗精神分裂症。
Cochrane Database Syst Rev. 2015 Feb 5;2015(2):CD000307. doi: 10.1002/14651858.CD000307.pub2.
4
Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders.癸酸氟哌噻吨(长效制剂)用于治疗精神分裂症或其他类似的精神障碍。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD001470. doi: 10.1002/14651858.CD001470.pub2.
5
Fluphenazine (oral) versus placebo for schizophrenia.口服氟奋乃静治疗精神分裂症与安慰剂对照
Cochrane Database Syst Rev. 2013 Jul 17;7(7):CD006352. doi: 10.1002/14651858.CD006352.pub2.
6
Targeted intermittent treatment in chronic schizophrenia.慢性精神分裂症的靶向间歇性治疗
Front Psychiatry. 2013 Mar 14;4:13. doi: 10.3389/fpsyt.2013.00013. eCollection 2013.
7
Dose response and atypical antipsychotics in schizophrenia.精神分裂症中的剂量反应与非典型抗精神病药物
CNS Drugs. 2004;18(9):597-616. doi: 10.2165/00023210-200418090-00005.
8
Neuroleptic drug utilization in out-patients--a prescription database study.门诊患者抗精神病药物的使用——一项处方数据库研究。
Br J Clin Pharmacol. 1993 Dec;36(6):579-83. doi: 10.1111/j.1365-2125.1993.tb00418.x.
9
Fluvoxamine as an adjunctive agent in schizophrenia.氟伏沙明作为精神分裂症的辅助药物。
CNS Drug Rev. 2001 Fall;7(3):283-304. doi: 10.1111/j.1527-3458.2001.tb00200.x.
10
Depot haloperidol decanoate for schizophrenia.用于精神分裂症的长效癸酸氟哌啶醇
Cochrane Database Syst Rev. 2000;1999(2):CD001361. doi: 10.1002/14651858.CD001361.